Benadryl

Lung Neoplasm

Merck Sharp & Dohme LLCPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

10 Active assets in the Lung Neoplasm cohort.

Asset / Sponsor	Phase	Rating
BELAGENPUMATUCEL-L (SK-LU-1) NovaRx Corporation	Phase 3	BB
Nivolumab Hospital Israelita Albert Einstein	Phase 2	BB
Rivoceranib Fuzhou General Hospital	Phase 3	BB
Pralsetinib, trans- Hoffmann-La Roche	Phase 3	BB
TRASTUZUMAB Cancer Research UK	Phase 2/3	B

View all 20 →

Same molecule, other indications

Benadryl is also rated in:

Relapsing Chronic Myelogenous LeukemiaDormant

BBB

Indicative ·

74 / 100

Recurrent Adult Hodgkin LymphomaDormant

BBB

Indicative ·

74 / 100

Recurrent Adult Acute Myeloid LeukemiaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.